Trial · NCT03470922
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 50
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Arm A: Relatlimab + Nivolumab | 10.12 | 95% Confidence Interval 6.37 to 15.74 | Months | |
| Progression Free Survival (PFS) | Arm B: Nivolumab | 4.63 | 95% Confidence Interval 3.38 to 5.62 | Months | |
| The Number of Participants Experiencing Adverse Events (AEs) | Arm A: Relatlimab + Nivolumab | 345 | Participants | ||
| The Number of Participants Experiencing Adverse Events (AEs) | Arm B: Nivolumab | 339 | Participants | ||
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | Arm A: Relatlimab + Nivolumab | 121 | Participants | ||
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | Arm B: Nivolumab | 105 | Participants | ||
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | Arm A: Relatlimab + Nivolumab | 69 | Participants | ||
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | Arm B: Nivolumab | 41 | Participants | ||
| The Number of Participant Deaths in the Study | Arm A: Relatlimab + Nivolumab | 108 | Participants | ||
| The Number of Participant Deaths in the Study | Arm B: Nivolumab | 119 | Participants | ||
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm A: Relatlimab + Nivolumab | ALT OR AST > 3XULN | 26 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm B: Nivolumab | ALT OR AST > 3XULN | 15 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm A: Relatlimab + Nivolumab | ALT OR AST> 5XULN | 11 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm B: Nivolumab | ALT OR AST> 5XULN | 7 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm A: Relatlimab + Nivolumab | ALT OR AST> 10XULN | 4 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm B: Nivolumab | ALT OR AST> 10XULN | 4 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm A: Relatlimab + Nivolumab | ALT OR AST > 20XULN | 0 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm B: Nivolumab | ALT OR AST > 20XULN | 2 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm A: Relatlimab + Nivolumab | TOTAL BILIRUBIN > 2XULN | 2 | Participants | |
| The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests | Arm B: Nivolumab | TOTAL BILIRUBIN > 2XULN | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03470922/results